Early Development & Drug Safety (EDDS)

E-001 - EFFECT OF PAROXETINE OR QUETIAPINE COMBINED WITH OXYCODONE VS OXYCODONE ALONE ON VENTILATION DURING HYPERCAPNIA: A RANDOMIZED CLINICAL TRIAL.

EP-029 - IDENTIFICATION OF A SAFE AND TOLERABLE CARBAMAZEPINE DOSING PARADIGM THAT FACILITATES EFFECTIVE CYP3A INDUCTION EVALUATION.

EP-032 - A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS.

LB-003 - A PHASE I, RANDOMIZED, OPEN-LABEL, CROSSOVER, FIXED-SEQUENCE STUDY TO EVALUATE THE PK, D0SE-PROPORTIONALITY, BIOAVAILABILITY, AND TOLERABILITY OF SUBCUTANEOUS LEVOTHYROXINE SODIUM (XP-8121) IN HEALTHY ADULT SUBJECTS.

PII-012 - FROM RIFAMPIN TO CARBAMAZEPINE: HOW TO PROPERLY MANAGE SAFETY IN A CHANGING DRUG-DRUG-INTERACTION TRIAL LANDSCAPE.

PII-013 - IN VITRO, IN SILICO, AND CLINICAL INVESTIGATIONS OF BLU-5937 AS PERPETRATOR OF DRUG-DRUG INTERACTIONS.

PII-014 - PHARMACOKINETIC DRUG INTERACTION BETWEEN FEXUPRAZAN (DWP14012), A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN HEALTHY SUBJECTS.

PII-016 - PHARMACOKINETICS OF SHIP1 INHIBITORS IN MICE: COMPARISON OF IN SILICO AND IN VIVO PHARMACOKINETICS.

PII-018 - THE PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VUTIGLABRIDIN, A SYNTHETIC GLABRIDIN DERIVATIVE, AFTER MULTIPLE ADMINISTRATION IN OBESE SUBJECTS.